Chester County News and Community Website
PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) released its financial results for the second quarter ended June 30, 2024. The company also provided updates on its ongoing clinical and …
Carisma Therapeutics Reports Progress and Financial Results for Q2 2024 Read More PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) announced its participation in the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024. The event will …
Carisma Therapeutics to Present at AASLD 2024 on Liver Fibrosis Treatment Read More PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) announced the recent appointment of Marella Thorell and Dr. David Scadden to its Board of Directors, which became effective June 30, 2024. …
Carisma Therapeutics Appoints New Board Members, Strengthens Leadership Read More PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) has announced the recent nomination of its first development candidate under a collaboration with Moderna, Inc. This candidate is an in vivo …
Carisma Therapeutics and Moderna Nominate New Cancer Therapy Candidate Read More PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) announced that Steven Kelly, its President and Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Cell Therapy …
Carisma Therapeutics CEO to Speak at Stifel 2024 Cell Therapy Forum Read More PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its innovative cancer treatment, CT-0525. This therapy targets …
FDA Grants Fast Track Status to Carisma Therapeutics’ New Cancer Therapy Read More PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) announced that Steven Kelly, President and CEO, will participate in a fireside chat at the Jefferies Global Healthcare Conference. The event is …
Carisma Therapeutics CEO to Speak at Jefferies Global Healthcare Conference Read More PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) has announced a significant milestone in cancer treatment. The company recently dosed the first patient in its Phase 1 clinical trial of …
Carisma Therapeutics Launches First Human Trial for CAR-Monocyte Therapy Read More PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM), a pioneering firm in the field of cancer treatment, has unveiled a series of strategic changes alongside its financial results for the …
Carisma Therapeutics Announces Restructuring and Pipeline Reprioritization Amid Quarterly Financial Report Read More PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM), a pioneering biotechnology firm, has unveiled promising preclinical data for an innovative treatment approach to liver fibrosis, a condition currently posing significant …
Carisma Therapeutics Showcases Breakthrough in Liver and Lung Fibrosis Treatment Read More